Salute e Benessere

Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant…

Reduction in distant recurrence consistently deepened beyond 3-year Kisqali treatment duration in patients with node-positive (N+) and high-risk node-negative (N0) disease, as well as between anatomical stages 1 Real-world 5-year distant recurrence data in high-risk patients with HR+/HER2- early breast cancer (EBC), regardless of nodal status, highlights importance of adding a CDK4/6 inhibitor to endocrine therapy for all eligible patients 2 Late-breaking Kisqali data...
Nasdaq GlobeNewswire
10/12/2024

LILYSILK Reflects on a Year of Giving Back Through Global Nonprofit Partnerships

On the health front, LILYSILK's partnership with NBCF has enabled critical support for women facing breast cancer. With a donation of $10,718, the brand has funded 20 women to be educated on their breast health, 77 patients supported by Patient Navigators, and provided 13 mammograms, among other impactful programs. LILYSILK's contributions also supported the distribution of HOPE Kits and volunteer-driven initiatives aimed at uplifting patients during their journeys. On the health front,...
PR Newswire
10/12/2024

Ori Biotech and Fresenius Kabi Collaborate to Advance Modular, Scalable…

New collaboration showcases successful integration of Ori's IRO Platform with Cue and Lovo processing systems to enhance efficiency in CGT manufacturing LONDON and BAD HOMBURG, Germany, Dec.10, 2024(GLOBE NEWSWIRE) --Ori Biotech Ltd. (Ori), a leader in cell and gene therapy (CGT) manufacturing technology, andFresenius Kabi, an operating company of Fresenius, today announced a collaboration to integrate the IRO ®platform with Fresenius Kabi's upstream and downstream processing...
Nasdaq GlobeNewswire
10/12/2024

Endo Launches Doxycycline for Injection, USP

According to IQVIA®, doxycycline for injection 100 mg vial sales were approximately $49 million for the 12 months ended September 30, 2024. According to IQVIA ®, doxycycline for injection 100 mg vial sales were approximately $49 million for the 12 months ended September 30, 2024. DOXY 100 ™is a trademark of Fresenius Kabi. About EndoEndo is a diversified specialty pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members...
PR Newswire
10/12/2024

Infinix Introduces Vibrant New Colors for the HOT 50 Series: A Bold Lifestyle…

Available in three inspiring colors—Aurora Green, symbolizing harmony and joy; Rising Red, radiating energy and fortune; and Blossom Pink, celebrating growth and flourishing aspirations—it redefines style and resilience. Complementing this premium material, the Pro+ features a World's Slimmest 3D-Curved SlimEdge Design, AMOLED display with Corning® Gorilla® Glass, and TÜV-certified 5-year fluency and 4-year long-lasting battery, making it a seamless companion for modern lifestyles. Available…
PR Newswire
10/12/2024

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval…

~ U.S. Food and Drug Administration (FDA) agrees that data from ongoing Phase I/II studies compared to a natural history external control may serve as the primary basis for a Biologics License Application (BLA) for Accelerated Approval ~~ FDA agrees that the composite Unified Huntington's Disease Rating Scale (cUHDRS) may serve as an intermediate clinical endpoint for Accelerated Approval ~ ~ Conference call today at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, Dec...
Nasdaq GlobeNewswire
10/12/2024

SUANNUTRA Launches Innovative Platform for Dietary Supplement Concept Creation

A New Blend with SuanBlend A New Blend with SuanBlend SuanNutra's innovative custom blends service—SuanBlend—provides a comprehensive solution for the European Market. The new service combines the branded ingredients of Monteloeder, S.L., with the comprehensive functionals ingredients line of Gonmisol, S.L., both companies are subsidiaries of SUANNUTRA This comprehensive service provides a unique solution for companies seeking a strategic partner capable of supplying both high-value...
PR Newswire
10/12/2024

AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060…

AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome ACI-24.060 was generally safe and well tolerated in individuals with Down syndrome with no serious adverse events related to the study drugNo cases of amyloid-related imaging abnormalities observed in this study populationBased upon these findings, AC Immune plans to open the high-dose cohort in ABATE in individuals with Down syndromeLausanne, Switzerland, December 10, 2024– AC...
Nasdaq GlobeNewswire
10/12/2024

CEPI and Accumulus Synergy team up to enhance information equity and accelerate…

Supported by $19.1 million in funding from CEPI, the regulatory collaboration platform developed by global non-profit Accumulus Synergy, could enhance access to medical countermeasures by bolstering information equity. The platform seeks to enable regulatory authorities—responsible for approving new health products—to simultaneously review standardised, pertinent data on vaccine safety, efficacy and quality, allowing them to approve a health product based on that shared assessment—a process...
Nasdaq GlobeNewswire
10/12/2024

Medical Elastomer Market worth $14.27 billion by 2029 - Exclusive Report by…

210 – Tables45 – Figures250 – Pages 210 – Tables 45 – Figures 250 – Pages Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=191173877 The medical elastomer market is driven by the growing demand of medical devices fueled by expansion of healthcare technologies. Medical devices such as surgical instruments and diagnostic tools need components which are durable, flexible and biocompatible. The medical elastomers offer these properties. Additionally,...
PR Newswire
10/12/2024

Kling Biotherapeutics Strengthens Leadership Team to Advance Pipeline Using its…

Michael Koslowski, Chief Executive Officer at Kling Biotherapeutics, said: "Alessandra and Rob's appointments come at a pivotal time of growth and development for Kling. By utilizing our groundbreaking commercially validated primary B-cell selection and evolution platform to identify therapeutic antibodies from B-cells of 'exceptional responders', we are laser-focused on developing best-in-class therapeutics for cancer and infectious diseases." Michael Koslowski, Chief Executive…
PR Newswire
10/12/2024

Resolution Therapeutics Announces Presentation at Keystone Symposia on Fibrosis

Details of the poster presentation: Details of the poster presentation: Title : Nonclinical program to enable a Phase1/2 trial of engineered pro-regenerative macrophages for the treatment of end stage liver disease. Publication Number : 1044 Session Date and Time : Poster Session #1, 9 thof December,7:30:00 PM (GMT -8) Presenter :Keith Sutton, PhD – Director, Pre-Clinical Development at Resolution Therapeutics NOTES TO EDITORS About RTX001 RTX001 is an...
PR Newswire
10/12/2024

SKAN Research Trust Secures Two Major Government Recognitions: Research…

This milestone achievement follows another significant landmark when the Department of Scientific and Industrial Research, Government of India, recognized SKAN as a Scientific and Industrial Research Organization (SIRO). The SIRO recognition is an acknowledgment of the multiple patents and research papers published by SKAN scientists, which range from the use of AI in disease management and bioinformatics to large community studies that aid public health. This milestone achievement follows...
PR Newswire
10/12/2024

Vivoryon Therapeutics N.V. Reports Q3 2024 Results and Highlights Progress on…

Vivoryon Therapeutics N.V. Reports Q3 2024 Results and Highlights Progress on Varoglutamstat in Kidney Disease Varoglutamstat Phase 2 program shows highly consistent, statistically significant and clinically meaningful improvement of kidney function (eGFR 1 ) versus placebo in two independent randomized double-blind placebo-controlled studiesVIVA-MIND topline analysis of kidney function data reported yesterday provides a second Phase 2 long-term dataset demonstrating...
Nasdaq GlobeNewswire
10/12/2024

Santhera Receives Positive Recommendation from NICE for AGAMREE® (Vamorolone) as…

Santhera Receives Positive Recommendation from NICE for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy AGAMREE® has been recommended by NICE for treating Duchenne muscular dystrophy (DMD) in patients 4 years of age and older in England, Wales and Northern IrelandSanthera will be working closely with NHS England, NHS Wales and NHS Northern Ireland to ensure rapid patient access Santhera also pursuing reimbursement via the Scottish Medicines Consortium (SMC) to...
Nasdaq GlobeNewswire
10/12/2024

New and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024…

Long-term data confirm fixed-duration Columvi and Lunsumio achieve durable remissions beyond the end of treatment, with real-world data suggesting reduced treatment-related travel burden due to less frequent dosing 1,2,3 First presentation of Lunsumio given subcutaneously showed non-inferiority to intravenous treatment with a consistent safety profile, potentially providing an additional outpatient option with a shorter administration time 4 Positive results for...
Nasdaq GlobeNewswire
10/12/2024

The Changing Market Dynamics of Immune Thrombocytopenia, Aplastic Anemia, and…

DelveInsight has recently released a series of epidemiology-based market reports focusing on blood disorders including Immune Thrombocytopenia, Aplastic Anemia, and Diamond-Blackfan Anemia. These reports include a comprehensive understanding of current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034 segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and…
PR Newswire
09/12/2024

Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for…

it has commenced a tender offer for all of the outstanding shares of common stock of Poseida Therapeutics, Inc. (Poseida) (NASDAQ: PSTX) at a price of $9.00 per share in cash, plus a non-tradeable contingent value right (CVR) to receive certain contingent payments of up to an aggregate of $4.00 per share in cash. The tender offer is being made pursuant to the previously announced merger agreement dated as of November 25, 2024 among Roche Holdings, Inc., an indirect wholly owned subsidiary of...
Nasdaq GlobeNewswire
09/12/2024

NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in…

Investigators concluded that the encouraging oncologic outcomes coupled with a favorable safety profile warrant further evaluation in a randomized trial23 months median Overall Survival from date of diagnosis was observed in 22 patients with locally advanced or borderline resectable pancreatic cancerUS FDA approved protocol amendment to launch new cohort evaluating RT-activated NBTXR3 combined with standard-of-care concurrent chemotherapy and recruitment is ongoingFull data from...
Nasdaq GlobeNewswire
09/12/2024

EUROAPI moves into a new chapter with new Governance and Leadership 

Press Release Emmanuel Blin appointed Independent Chair of the Board of DirectorsDavid Seignolle appointed Chief Executive OfficerFull-year 2024 guidance maintained Paris – December 9, 2024 –With FOCUS-27 strategic plan foundations established and its financing secured, EUROAPI moves into a new chapter. The company's Board of Directors has accepted today the resignation of Viviane Monges as Director and Chair of the Board and Ludwig de Mot as Chief...
Nasdaq GlobeNewswire
09/12/2024

Press Release: ASH: Sarclisa combinations demonstrated significant benefits in…

ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patientsNew analysis from the IMROZ phase 3 study of Sarclisa-VRd demonstrated higher and sustained MRD negativity rates in transplant- ineligibleNDMM patients versus VRd aloneNew detailed results from the GMMG-HD7 phase 3 study of Sarclisa-RVd induction therapy resulted in a significant and clinically meaningful PFS benefit with deeper MRD negativity in transplant- eligibleNDMM patients...
Nasdaq GlobeNewswire
09/12/2024

Direct Thrombin Inhibitors Market Expands with Innovations in Cardiovascular…

Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-9H18525/Global_Direct_Thrombin_Inhibitors_DTIs Claim Your Free Report:https://reports.valuates.com/request/sample/QYRE-Auto-9H18525/Global_Direct_Thrombin_Inhibitors_DTIs Major Factors Driving the Growth of Direct Thrombin Inhibitors Market: The Direct Thrombin Inhibitors (DTIs) market is experiencing significant growth, driven by the rising prevalence of thromboembolic disorders such as deep vein...
PR Newswire
09/12/2024

Ipsen - November 2024 - Monthly information relative to the total number of…

Monthly information relative to the total number of voting rightsand shares composing the share capital(in accordance with Article L.233-8 II of the French Commercial Code andArticle 223-16 of the General Regulation of theAutorité des Marchés Financiers ) Market: Euronext ParisISIN Code: FR 0010259150 LEI: 549300M6SGDPB4Z94P11 DateTotal number of shares composing the share capitalTotal number of voting rights(1) 30 November 202483,814,526Gross...
Nasdaq GlobeNewswire
09/12/2024

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20)…

Media ReleaseCOPENHAGEN, Denmark; December 9, 2024 Results from Arm 1 of the EPCORE ®NHL-2 trial show treatment with epcoritamab combination led to an overall response rate (ORR) of 100 percent and a complete response (CR) rate of 87 percent in high-risk patients with previously untreated diffuse large B-cell lymphoma (DLBCL)Extended follow-up data from EPCORE ®NHL-1 trial demonstrates durability of responses and long-term safety of epcoritamab monotherapy for patients...
Nasdaq GlobeNewswire
09/12/2024
Altri  Comunicati